Donepezil Market By Dosage Strength (5mg, 10mg, 23mg) , By Route of Administeration (Oral, Transdermal) By Distribution Channel (Hospital Pharmacies, Drug stores and Retail Pharmacies, Online Providers) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The donepezil market was valued at $0.9 billion in 2023, and is projected to reach $1.1 billion by 2033, growing at a CAGR of 1.9% from 2024 to 2033.
Donepezil is a medication primarily used to treat symptoms of Alzheimer's disease and other forms of dementia. It belongs to a class of drugs known as acetylcholinesterase inhibitors, which work by increasing the levels of acetylcholine, a neurotransmitter involved in memory and cognitive function. Donepezil does not cure Alzheimer's, but it can help slow the progression of symptoms such as memory loss, confusion, and difficulties in thinking or reasoning, especially in the early to moderate stages of the disease.
The growth of the global donepezil market is driven by alarming rise in the prevalence of Alzheimer's and other dementias. According to a study published by the BrightFocus Foundation—a non-profit organization that funds exceptional scientific research worldwide to defeat Alzheimer’s disease, macular degeneration, and glaucoma—approximately 55 million individuals are estimated to be suffering from Alzheimer’s or other dementias. This number is anticipated to rise to 152 million by 2050. In addition, increase in awareness about Alzheimer’s disease and improved diagnostic capabilities lead to higher rates of diagnosis, contributing to the market growth. Moreover, surge in geriatric population acts as the key driving force of the global market. This is attributed to the fact that as people age, the brain naturally undergoes neurodegeneration, characterized by the loss of neurons and synapses, which is associated with cognitive decline and Alzheimer’s. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, the introduction of generic versions of Donepezil offers more affordable treatment options, expanding the market reach and increasing patient adherence. However, common side effects of Donepezil, such as nausea, diarrhea, insomnia, and muscle cramps, can lead to treatment discontinuation or non-adherence among patients, thus impacting the market growth. In addition, the development of alternative treatments for Alzheimer's, including other medications and non-pharmacological interventions, can limit the demand for donepezil. On the contrary, ongoing research into Alzheimer's treatments and the efficacy of donepezil spurs the market interest, as new formulations or combinations with other therapies may enhance treatment outcomes. Such developments are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.
The global donepezil market is segmented into dosage strength, route of administration, distribution channel, and region. On the basis of the dosage strength, the market is categorized into 5mg, 10mg, and 23mg. By route of administration, it is classified into oral and transdermal. Depending on distribution channel, it is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By dosage strength, the 5 mg segment is expected to dominate the market from 2024 to 2033.
On the basis of route of administration, the oral segment is anticipated to exhibit the highest growth during the forecast period.
Depending on distribution channel, the drug stores & retail pharmacies segment held a substantial portion of the donepezil market share.
Region wise, North America is poised to maintain its leadership in the donepezil market in the coming years.
Competition Analysis
Competitive analysis and profiles of the major players in the global donepezil market include Eisai Co., Ltd. , Alteus, Corium, LLC. , DD Pharmaceuticals Pvt Ltd, Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Cipla, and Alkem. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.
Additional benefits you will get with this purchase are:
By Dosage Strength
Donepezil is a medication primarily used to treat symptoms of Alzheimer's disease and other forms of dementia. It belongs to a class of drugs known as acetylcholinesterase inhibitors, which work by increasing the levels of acetylcholine, a neurotransmitter involved in memory and cognitive function. Donepezil does not cure Alzheimer's, but it can help slow the progression of symptoms such as memory loss, confusion, and difficulties in thinking or reasoning, especially in the early to moderate stages of the disease.
The growth of the global donepezil market is driven by alarming rise in the prevalence of Alzheimer's and other dementias. According to a study published by the BrightFocus Foundation—a non-profit organization that funds exceptional scientific research worldwide to defeat Alzheimer’s disease, macular degeneration, and glaucoma—approximately 55 million individuals are estimated to be suffering from Alzheimer’s or other dementias. This number is anticipated to rise to 152 million by 2050. In addition, increase in awareness about Alzheimer’s disease and improved diagnostic capabilities lead to higher rates of diagnosis, contributing to the market growth. Moreover, surge in geriatric population acts as the key driving force of the global market. This is attributed to the fact that as people age, the brain naturally undergoes neurodegeneration, characterized by the loss of neurons and synapses, which is associated with cognitive decline and Alzheimer’s. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, the introduction of generic versions of Donepezil offers more affordable treatment options, expanding the market reach and increasing patient adherence. However, common side effects of Donepezil, such as nausea, diarrhea, insomnia, and muscle cramps, can lead to treatment discontinuation or non-adherence among patients, thus impacting the market growth. In addition, the development of alternative treatments for Alzheimer's, including other medications and non-pharmacological interventions, can limit the demand for donepezil. On the contrary, ongoing research into Alzheimer's treatments and the efficacy of donepezil spurs the market interest, as new formulations or combinations with other therapies may enhance treatment outcomes. Such developments are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.
The global donepezil market is segmented into dosage strength, route of administration, distribution channel, and region. On the basis of the dosage strength, the market is categorized into 5mg, 10mg, and 23mg. By route of administration, it is classified into oral and transdermal. Depending on distribution channel, it is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By dosage strength, the 5 mg segment is expected to dominate the market from 2024 to 2033.
On the basis of route of administration, the oral segment is anticipated to exhibit the highest growth during the forecast period.
Depending on distribution channel, the drug stores & retail pharmacies segment held a substantial portion of the donepezil market share.
Region wise, North America is poised to maintain its leadership in the donepezil market in the coming years.
Competition Analysis
Competitive analysis and profiles of the major players in the global donepezil market include Eisai Co., Ltd. , Alteus, Corium, LLC. , DD Pharmaceuticals Pvt Ltd, Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Cipla, and Alkem. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
By Dosage Strength
- 5mg
- 10mg
- 23mg
- Oral
- Transdermal
- Hospital Pharmacies
- Drug stores and Retail Pharmacies
- Online Providers
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Eisai Co., Ltd.
- Alteus
- Corium, LLC.
- DD Pharmaceuticals Pvt Ltd
- Intas Pharmaceuticals Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Sun Pharmaceutical
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- Cipla
- Alkem
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: DONEPEZIL MARKET, BY DOSAGE STRENGTH
4.1. Market Overview
4.1.1 Market Size and Forecast, By Dosage Strength
4.2. 5mg
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. 10mg
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. 23mg
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Route Of Administeration
5.2. Oral
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Transdermal
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL
6.1. Market Overview
6.1.1 Market Size and Forecast, By Distribution Channel
6.2. Hospital Pharmacies
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Drug Stores And Retail Pharmacies
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Online Providers
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
CHAPTER 7: DONEPEZIL MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Dosage Strength
7.2.3. Market Size and Forecast, By Route Of Administeration
7.2.4. Market Size and Forecast, By Distribution Channel
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Donepezil Market
7.2.6.1. Market Size and Forecast, By Dosage Strength
7.2.6.2. Market Size and Forecast, By Route Of Administeration
7.2.6.3. Market Size and Forecast, By Distribution Channel
7.2.7. Canada Donepezil Market
7.2.7.1. Market Size and Forecast, By Dosage Strength
7.2.7.2. Market Size and Forecast, By Route Of Administeration
7.2.7.3. Market Size and Forecast, By Distribution Channel
7.2.8. Mexico Donepezil Market
7.2.8.1. Market Size and Forecast, By Dosage Strength
7.2.8.2. Market Size and Forecast, By Route Of Administeration
7.2.8.3. Market Size and Forecast, By Distribution Channel
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Dosage Strength
7.3.3. Market Size and Forecast, By Route Of Administeration
7.3.4. Market Size and Forecast, By Distribution Channel
7.3.5. Market Size and Forecast, By Country
7.3.6. Germany Donepezil Market
7.3.6.1. Market Size and Forecast, By Dosage Strength
7.3.6.2. Market Size and Forecast, By Route Of Administeration
7.3.6.3. Market Size and Forecast, By Distribution Channel
7.3.7. France Donepezil Market
7.3.7.1. Market Size and Forecast, By Dosage Strength
7.3.7.2. Market Size and Forecast, By Route Of Administeration
7.3.7.3. Market Size and Forecast, By Distribution Channel
7.3.8. UK Donepezil Market
7.3.8.1. Market Size and Forecast, By Dosage Strength
7.3.8.2. Market Size and Forecast, By Route Of Administeration
7.3.8.3. Market Size and Forecast, By Distribution Channel
7.3.9. Italy Donepezil Market
7.3.9.1. Market Size and Forecast, By Dosage Strength
7.3.9.2. Market Size and Forecast, By Route Of Administeration
7.3.9.3. Market Size and Forecast, By Distribution Channel
7.3.10. Spain Donepezil Market
7.3.10.1. Market Size and Forecast, By Dosage Strength
7.3.10.2. Market Size and Forecast, By Route Of Administeration
7.3.10.3. Market Size and Forecast, By Distribution Channel
7.3.11. Rest Of Europe Donepezil Market
7.3.11.1. Market Size and Forecast, By Dosage Strength
7.3.11.2. Market Size and Forecast, By Route Of Administeration
7.3.11.3. Market Size and Forecast, By Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Dosage Strength
7.4.3. Market Size and Forecast, By Route Of Administeration
7.4.4. Market Size and Forecast, By Distribution Channel
7.4.5. Market Size and Forecast, By Country
7.4.6. Japan Donepezil Market
7.4.6.1. Market Size and Forecast, By Dosage Strength
7.4.6.2. Market Size and Forecast, By Route Of Administeration
7.4.6.3. Market Size and Forecast, By Distribution Channel
7.4.7. China Donepezil Market
7.4.7.1. Market Size and Forecast, By Dosage Strength
7.4.7.2. Market Size and Forecast, By Route Of Administeration
7.4.7.3. Market Size and Forecast, By Distribution Channel
7.4.8. India Donepezil Market
7.4.8.1. Market Size and Forecast, By Dosage Strength
7.4.8.2. Market Size and Forecast, By Route Of Administeration
7.4.8.3. Market Size and Forecast, By Distribution Channel
7.4.9. Australia Donepezil Market
7.4.9.1. Market Size and Forecast, By Dosage Strength
7.4.9.2. Market Size and Forecast, By Route Of Administeration
7.4.9.3. Market Size and Forecast, By Distribution Channel
7.4.10. South Korea Donepezil Market
7.4.10.1. Market Size and Forecast, By Dosage Strength
7.4.10.2. Market Size and Forecast, By Route Of Administeration
7.4.10.3. Market Size and Forecast, By Distribution Channel
7.4.11. Rest of Asia-Pacific Donepezil Market
7.4.11.1. Market Size and Forecast, By Dosage Strength
7.4.11.2. Market Size and Forecast, By Route Of Administeration
7.4.11.3. Market Size and Forecast, By Distribution Channel
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Dosage Strength
7.5.3. Market Size and Forecast, By Route Of Administeration
7.5.4. Market Size and Forecast, By Distribution Channel
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Donepezil Market
7.5.6.1. Market Size and Forecast, By Dosage Strength
7.5.6.2. Market Size and Forecast, By Route Of Administeration
7.5.6.3. Market Size and Forecast, By Distribution Channel
7.5.7. Saudi Arabia Donepezil Market
7.5.7.1. Market Size and Forecast, By Dosage Strength
7.5.7.2. Market Size and Forecast, By Route Of Administeration
7.5.7.3. Market Size and Forecast, By Distribution Channel
7.5.8. South Africa Donepezil Market
7.5.8.1. Market Size and Forecast, By Dosage Strength
7.5.8.2. Market Size and Forecast, By Route Of Administeration
7.5.8.3. Market Size and Forecast, By Distribution Channel
7.5.9. Rest of LAMEA Donepezil Market
7.5.9.1. Market Size and Forecast, By Dosage Strength
7.5.9.2. Market Size and Forecast, By Route Of Administeration
7.5.9.3. Market Size and Forecast, By Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping Of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Eisai Co., Ltd.
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Alteus
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Corium, LLC.
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. DD Pharmaceuticals Pvt Ltd
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. Intas Pharmaceuticals Ltd.
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Dr. Reddy’s Laboratories Ltd.
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Sun Pharmaceutical
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Cipla
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. Alkem
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: DONEPEZIL MARKET, BY DOSAGE STRENGTH
4.1. Market Overview
4.1.1 Market Size and Forecast, By Dosage Strength
4.2. 5mg
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. 10mg
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. 23mg
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Route Of Administeration
5.2. Oral
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Transdermal
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL
6.1. Market Overview
6.1.1 Market Size and Forecast, By Distribution Channel
6.2. Hospital Pharmacies
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Drug Stores And Retail Pharmacies
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Online Providers
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
CHAPTER 7: DONEPEZIL MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Dosage Strength
7.2.3. Market Size and Forecast, By Route Of Administeration
7.2.4. Market Size and Forecast, By Distribution Channel
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Donepezil Market
7.2.6.1. Market Size and Forecast, By Dosage Strength
7.2.6.2. Market Size and Forecast, By Route Of Administeration
7.2.6.3. Market Size and Forecast, By Distribution Channel
7.2.7. Canada Donepezil Market
7.2.7.1. Market Size and Forecast, By Dosage Strength
7.2.7.2. Market Size and Forecast, By Route Of Administeration
7.2.7.3. Market Size and Forecast, By Distribution Channel
7.2.8. Mexico Donepezil Market
7.2.8.1. Market Size and Forecast, By Dosage Strength
7.2.8.2. Market Size and Forecast, By Route Of Administeration
7.2.8.3. Market Size and Forecast, By Distribution Channel
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Dosage Strength
7.3.3. Market Size and Forecast, By Route Of Administeration
7.3.4. Market Size and Forecast, By Distribution Channel
7.3.5. Market Size and Forecast, By Country
7.3.6. Germany Donepezil Market
7.3.6.1. Market Size and Forecast, By Dosage Strength
7.3.6.2. Market Size and Forecast, By Route Of Administeration
7.3.6.3. Market Size and Forecast, By Distribution Channel
7.3.7. France Donepezil Market
7.3.7.1. Market Size and Forecast, By Dosage Strength
7.3.7.2. Market Size and Forecast, By Route Of Administeration
7.3.7.3. Market Size and Forecast, By Distribution Channel
7.3.8. UK Donepezil Market
7.3.8.1. Market Size and Forecast, By Dosage Strength
7.3.8.2. Market Size and Forecast, By Route Of Administeration
7.3.8.3. Market Size and Forecast, By Distribution Channel
7.3.9. Italy Donepezil Market
7.3.9.1. Market Size and Forecast, By Dosage Strength
7.3.9.2. Market Size and Forecast, By Route Of Administeration
7.3.9.3. Market Size and Forecast, By Distribution Channel
7.3.10. Spain Donepezil Market
7.3.10.1. Market Size and Forecast, By Dosage Strength
7.3.10.2. Market Size and Forecast, By Route Of Administeration
7.3.10.3. Market Size and Forecast, By Distribution Channel
7.3.11. Rest Of Europe Donepezil Market
7.3.11.1. Market Size and Forecast, By Dosage Strength
7.3.11.2. Market Size and Forecast, By Route Of Administeration
7.3.11.3. Market Size and Forecast, By Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Dosage Strength
7.4.3. Market Size and Forecast, By Route Of Administeration
7.4.4. Market Size and Forecast, By Distribution Channel
7.4.5. Market Size and Forecast, By Country
7.4.6. Japan Donepezil Market
7.4.6.1. Market Size and Forecast, By Dosage Strength
7.4.6.2. Market Size and Forecast, By Route Of Administeration
7.4.6.3. Market Size and Forecast, By Distribution Channel
7.4.7. China Donepezil Market
7.4.7.1. Market Size and Forecast, By Dosage Strength
7.4.7.2. Market Size and Forecast, By Route Of Administeration
7.4.7.3. Market Size and Forecast, By Distribution Channel
7.4.8. India Donepezil Market
7.4.8.1. Market Size and Forecast, By Dosage Strength
7.4.8.2. Market Size and Forecast, By Route Of Administeration
7.4.8.3. Market Size and Forecast, By Distribution Channel
7.4.9. Australia Donepezil Market
7.4.9.1. Market Size and Forecast, By Dosage Strength
7.4.9.2. Market Size and Forecast, By Route Of Administeration
7.4.9.3. Market Size and Forecast, By Distribution Channel
7.4.10. South Korea Donepezil Market
7.4.10.1. Market Size and Forecast, By Dosage Strength
7.4.10.2. Market Size and Forecast, By Route Of Administeration
7.4.10.3. Market Size and Forecast, By Distribution Channel
7.4.11. Rest of Asia-Pacific Donepezil Market
7.4.11.1. Market Size and Forecast, By Dosage Strength
7.4.11.2. Market Size and Forecast, By Route Of Administeration
7.4.11.3. Market Size and Forecast, By Distribution Channel
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Dosage Strength
7.5.3. Market Size and Forecast, By Route Of Administeration
7.5.4. Market Size and Forecast, By Distribution Channel
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Donepezil Market
7.5.6.1. Market Size and Forecast, By Dosage Strength
7.5.6.2. Market Size and Forecast, By Route Of Administeration
7.5.6.3. Market Size and Forecast, By Distribution Channel
7.5.7. Saudi Arabia Donepezil Market
7.5.7.1. Market Size and Forecast, By Dosage Strength
7.5.7.2. Market Size and Forecast, By Route Of Administeration
7.5.7.3. Market Size and Forecast, By Distribution Channel
7.5.8. South Africa Donepezil Market
7.5.8.1. Market Size and Forecast, By Dosage Strength
7.5.8.2. Market Size and Forecast, By Route Of Administeration
7.5.8.3. Market Size and Forecast, By Distribution Channel
7.5.9. Rest of LAMEA Donepezil Market
7.5.9.1. Market Size and Forecast, By Dosage Strength
7.5.9.2. Market Size and Forecast, By Route Of Administeration
7.5.9.3. Market Size and Forecast, By Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping Of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Eisai Co., Ltd.
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Alteus
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Corium, LLC.
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. DD Pharmaceuticals Pvt Ltd
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. Intas Pharmaceuticals Ltd.
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Dr. Reddy’s Laboratories Ltd.
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Sun Pharmaceutical
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Cipla
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. Alkem
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
